Media about us

  • 23 January 2018

    Blockchain as a technology goes far beyond cryptocurrency application. Interview with Maxim Gorbachev, Managing Partner at RMI Partners

    Blockchain as a technology goes far beyond cryptocurrency application. Interview with Maxim Gorbachev, Managing Partner at RMI Partners

    #WBSMoscow

    As the blockchain revolution gains momentum around the world, Trescon had the opportunity to interview Maxim Gorbachev, a Managing Partner at RMI Partners, on the evolving nature of blockchain. RMI Partners is a venture capital company established in 2012, with a strategic focus on investments supporting the development of innovative biopharmaceutical products and medical technologies.

  • 22 January 2018

    Russia grants Hermes GMP certification at German and Austrian plants

    Russia grants Hermes GMP certification at German and Austrian plants

    Dan Stanton / In-Pharma Technologist.com

    Since 2011, Russian policy has favoured local production in e􀃗orts to reduce reliance on pharmaceutical imports. Vladimir Putin’s ‘Pharma 2020’ policy pushes for as much 90% of drugs consumed in Russia to be made domestically by 2020. Such policies have led multinationals to tap the market through collaborations with domestic drugmakers. Pfizer, for example, teamed with Russian pharma firm NovaMedica last May to build an aseptic manufacturing plant in.

  • 19 January 2018

    Start Up Spotlight: OCON Medical Bets On A New 3D Copper Contraceptive Device

    Start Up Spotlight: OCON Medical Bets On A New 3D Copper Contraceptive Device

    Catherine Longworth / MedTech Insight

    Israeli start up OCON Medical is blazing a trail in the field of women's health with a new hormone-free contraceptive device. The company's IUB – intrauterine ball consists of copper pearls that prevent pregnancy locally within the uterus for five years.

  • 11 January 2018

    Genentech, Syndax expand HDAC-PD-L1 combination pact

    Genentech, Syndax expand HDAC-PD-L1 combination pact

    Nick Paul Taylor / FierceBiotech

    Genentech and Syndax have expanded their exploration of the effects of combining HDAC and PD-L1 inhibitors. The new agreement clears the Roche subsidiary to test its Tecentriq in combination with Syndax’s entinostat in a subset of breast cancer patients.

  • 28 December 2017

    NovaMedica Innotech R&D center meets Russian GMP standards

    NovaMedica Innotech R&D center meets Russian GMP standards

    GMP News

    NovaMedica, a Russian pharmaceutical company and investment project of RUSNANO, announced that it received the conclusion of the Russian Ministry of Industry and Trade on the compliance of the production site of NovaMedica Innotech R&D center, a subsidiary of NovaMedica, with the Russian Good Manufacturing Practice (GMP) standards.

  • 26 December 2017

    Authorities approve the application of NovaMedica for a new production facility

    Authorities approve the application of NovaMedica for a new production facility

    GMP News

    NovaMedica, a Russian pharmaceutical company and investment project of RUSNANO, announced that it received the approval of the Inter-Agency Commission for conclusion of Special Investment Contract (SPIC) under the investment project aimed at establishing a pharmaceutical plant for sterile injectable drugs in the Kaluga region.

  • 11 December 2017

    An Epic quest to detect cancer

    An Epic quest to detect cancer

    Bradley J. Fikes / The San-Diego Union Tribune

    Finding needles in a haystack is the life-and-death job of San Diego’s Epic Sciences. The needles are extremely rare cancer cells that hide among the millions of normal cells in the blood of cancer patients.

  • 27 November 2017

    Contract pharmaceutical manufacturing sites in Russia are very relevant

    Contract pharmaceutical manufacturing sites in Russia are very relevant

    GMP News

    A round table on Contract Manufacturing of Pharmaceutical Products was held on November 22, 2017, at Pharmtech & Ingredients 2017, the 19th international exhibition of equipment, raw materials and technologies for pharmaceutical manufacturing. The event moderator was Alexander Kuzin, the General Director at NovaMedica

  • 23 October 2017

    Contract R&D market is developing in Russia

    Contract R&D market is developing in Russia

    GMP News

    NovaMedica has launched in Moscow its R&D Center for development of new drug products. The Center is going to become attractive R&D site for customized developments and contract manufacturing.

  • 23 October 2017

    Russian pharmaceutical map has a new point of convergence

    Russian pharmaceutical map has a new point of convergence

    GMP News

    An interesting international pharmaceutical project has started in Russia. This project is a result of a convergence of interests of Rusnano, Russian state investment corporation, Domain Associates, an American venture capital foundation, and Pfizer, an American pharmaceutical corporation.  

All Portfolio

MEDIA CENTER

  • NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.

All news